Charles River Laboratories has signed a binding offer to acquire Citoxlab for €448 (~$510mn). The proposed transaction is expected to close in the second quarter of 2019.   Citoxlab is a non-clinical contract research organization (CRO), specializing in regulated safety assessment services, non-regulated discovery services, and medical device testing. With operations in Europe and North America, the proposed acquisition of Citoxlab would further strengthen Charles River’s position as a global ea...